Simon Clark has joined Polpharma as vice-president of the management board and chief commercial officer...
Polpharma’s services include EU standard dossiers for finished dosage formulations based on active pharmaceutical ingredients (API) developed in-house or outsourced. The company’s out-licensing (OL) portfolio secures the most comprehensive offer for its clients.
Co-operation with Polpharma can bring you several advantages, including:
- New products developed in three research and development (R&D) centers
- Very large portfolio to offer comprehensive dossiers
- Ten products in development and 20 products in early stage of development
- New products predominantly based on internally manufactured API
- Attractive products such as first generics, modern combo products and ophthalmic products without preservatives
- Dossiers meeting European guidelines adapted to local non-EU requirements
- Comprehensive manufacturing experience focused on lowering production cost
- Continuous out-licensing activity of our generic products with favourable conditions for our clients
This white paper outlines Polpharma B2B's finished dosage formulations (FDF) that are currently under development. Products...
Polpharma B2B is a significant European active pharmaceutical ingredient (API) producer with current good manufacturing...
Polpharma B2B's team of experts will be pleased to meet you at the CPhI Worldwide...